EMP is a relatively new FDA-approved agent for the management of type 2 diabetes (13), and recent findings have proved its efficacy in the management of type 1 diabetes as an adjunctive therapeutic agent added to insulin (14). This evidence concerns the gene INS and type 2 diabetes mellitus.